0001209191-23-056426.txt : 20231122
0001209191-23-056426.hdr.sgml : 20231122
20231122134857
ACCESSION NUMBER: 0001209191-23-056426
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231120
FILED AS OF DATE: 20231122
DATE AS OF CHANGE: 20231122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RENSCHLER MARKUS MD
CENTRAL INDEX KEY: 0001217598
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40499
FILM NUMBER: 231432561
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS INC
STREET 2: 995 E ARQUES AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085-4521
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662244
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455429901
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: BUILDING B, SUITE 450
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-285-4140
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: BUILDING B, SUITE 450
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-20
0
0001662244
Cyteir Therapeutics, Inc.
CYT
0001217598
RENSCHLER MARKUS MD
C/O CYTEIR THERAPEUTICS, INC.
99 HAYDEN AVE, BUILDING B, SUITE 450
LEXINGTON
MA
02421
1
1
0
0
President and CEO
0
Common Stock
2023-11-20
4
M
0
56737
1.69
A
1045473
D
Common Stock
2023-11-20
4
M
0
27900
1.20
A
1073373
D
Stock Option (Right to Buy)
1.69
2023-11-20
4
M
0
56737
0.00
D
2033-02-03
Common Stock
56737
245863
D
Stock Option (Right to Buy)
1.20
2023-11-20
4
M
0
27900
0.00
D
2030-02-24
Common Stock
27900
5073
D
Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023.
The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
/s/ David Gaiero, as attorney-in-fact for Markus Renschler, M.D.
2023-11-22